203 related articles for article (PubMed ID: 18666237)
21. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
Zhou J; Wen Q; Li SF; Zhang YF; Gao N; Tian X; Fang Y; Gao J; Cui MZ; He XP; Jia LJ; Jin H; Qiao HL
Oncotarget; 2016 Aug; 7(31):50612-50623. PubMed ID: 27203676
[TBL] [Abstract][Full Text] [Related]
22. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.
Byeon JY; Kim YH; Lee CM; Kim SH; Chae WK; Jung EH; Choi CI; Jang CG; Lee SY; Bae JW; Lee YJ
Arch Pharm Res; 2018 Sep; 41(9):921-930. PubMed ID: 30191460
[TBL] [Abstract][Full Text] [Related]
23. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
25. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences.
Oishi M; Chiba K; Malhotra B; Suwa T
Drug Metab Pharmacokinet; 2011 Jun; 26(3):236-41. PubMed ID: 21273733
[TBL] [Abstract][Full Text] [Related]
27. Single nucleotide and structural variants of CYP2D6 gene in Kinh Vietnamese population.
Nguyen HH; Ma TTH; Vu NP; Bach QTN; Vu TH; Nguyen TD; Nong HV
Medicine (Baltimore); 2019 May; 98(22):e15891. PubMed ID: 31145348
[TBL] [Abstract][Full Text] [Related]
28. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
Yin SJ; Ni YB; Wang SM; Wang X; Lou YQ; Zhang GL
J Clin Pharm Ther; 2012 Jun; 37(3):364-9. PubMed ID: 21913948
[TBL] [Abstract][Full Text] [Related]
29. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
30. Determinants of Cytochrome P450 2D6 mRNA Levels in Healthy Human Liver Tissue.
Ning M; Duarte JD; Stevison F; Isoherranen N; Rubin LH; Jeong H
Clin Transl Sci; 2019 Jul; 12(4):416-423. PubMed ID: 30821899
[TBL] [Abstract][Full Text] [Related]
31. Studies in 3,523 Norwegians and meta-analysis in 11,571 subjects indicate that variants in the hepatocyte nuclear factor 4 alpha (HNF4A) P2 region are associated with type 2 diabetes in Scandinavians.
Johansson S; Raeder H; Eide SA; Midthjell K; Hveem K; Søvik O; Molven A; Njølstad PR
Diabetes; 2007 Dec; 56(12):3112-7. PubMed ID: 17827402
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population.
Jin TB; Ma LF; Zhang JY; Yuan DY; Sun Q; Zong TY; Geng TT; Cui YL; Kang LL; Chen C
Gene; 2013 Sep; 527(1):360-5. PubMed ID: 23644254
[TBL] [Abstract][Full Text] [Related]
33. Novel genetic variations and haplotypes of hepatocyte nuclear factor 4alpha (HNF4A) found in Japanese type II diabetic patients.
Fukushima-Uesaka H; Saito Y; Maekawa K; Saeki M; Kamatani N; Kajio H; Kuzuya N; Yasuda K; Sawada J
Drug Metab Pharmacokinet; 2006 Aug; 21(4):337-46. PubMed ID: 16946562
[TBL] [Abstract][Full Text] [Related]
34. Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice.
Koh KH; Pan X; Shen HW; Arnold SL; Yu AM; Gonzalez FJ; Isoherranen N; Jeong H
J Biol Chem; 2014 Feb; 289(6):3105-13. PubMed ID: 24318876
[TBL] [Abstract][Full Text] [Related]
35. A non-coding genetic variant maximally associated with serum urate levels is functionally linked to HNF4A-dependent PDZK1 expression.
Ketharnathan S; Leask M; Boocock J; Phipps-Green AJ; Antony J; O'Sullivan JM; Merriman TR; Horsfield JA
Hum Mol Genet; 2018 Nov; 27(22):3964-3973. PubMed ID: 30124855
[TBL] [Abstract][Full Text] [Related]
36. P2 promoter variants of the hepatocyte nuclear factor 4alpha gene are associated with type 2 diabetes in Mexican Americans.
Lehman DM; Richardson DK; Jenkinson CP; Hunt KJ; Dyer TD; Leach RJ; Arya R; Abboud HE; Blangero J; Duggirala R; Stern MP
Diabetes; 2007 Feb; 56(2):513-7. PubMed ID: 17259399
[TBL] [Abstract][Full Text] [Related]
37. Contribution of hepatocyte nuclear factor-4 to down-regulation of CYP2D6 gene expression by nitric oxide.
Hara H; Adachi T
Mol Pharmacol; 2002 Jan; 61(1):194-200. PubMed ID: 11752221
[TBL] [Abstract][Full Text] [Related]
38. Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects.
Guo L; Wang S; Wan Z; Ni S; Xu B; Zhao X; Liu L
J Clin Pharm Ther; 2020 Aug; 45(4):632-637. PubMed ID: 32379356
[TBL] [Abstract][Full Text] [Related]
39. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.
Okubo M; Murayama N; Miura J; Chiba Y; Yamazaki H
Biochem Pharmacol; 2015 Jan; 93(1):104-9. PubMed ID: 25475885
[TBL] [Abstract][Full Text] [Related]
40. In vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population.
Dai DP; Geng PW; Wang SH; Cai J; Hu LM; Nie JJ; Hu JH; Hu GX; Cai JP
Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):39-43. PubMed ID: 25469868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
